Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uprosertib - Novartis Oncology

Drug Profile

Uprosertib - Novartis Oncology

Alternative Names: GSK-2141795; GSK-2141795C; GSK-795; LAE 003; UPB 795

Latest Information Update: 21 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Dana-Farber Cancer Institute; National Cancer Institute (USA); National Comprehensive Cancer Network; Novartis Oncology; University of California at San Francisco
  • Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Endometrial cancer; Malignant melanoma; Multiple myeloma; Uveal melanoma
  • No development reported Lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 31 Jul 2018 Uprosertib licensed to Laekna Therapeutics worldwide
  • 24 Jun 2018 Biomarkers information updated
  • 03 Dec 2016 Efficacy data from a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top